Adding ursodeoxycholic acid to the endoscopic treatment and common bile duct stenting for large and multiple biliary stones: Will it improve the outcomes?

Table 2 Comparison of liver tests and reduction in the size and number of stone between two groups underwent to only CBD stenting (group A) and UDCA + CBD stenting (group B)

Variable	Control (Group A)	Intervention (Group B)	P-value*
Stone size in mm Mean (SD)	3.22 ± 1.31	4.09 ± 1.87	0.034
Number of stones Mean (SD)	3.34 ± 2.06	3.56 ± 2.26	0.67
Test, Unit#	Control (Group A)	Intervention (Group B)	P-value*
SGPT (ALT), U/L	184.38 ± 134.44	196.34 ± 114.5	0.754
SGOT (AST), U/L	141.31 ± 99.72	153.97 ± 114.5	0.639
Total Bilirubin, mg/dL	5.78 ± 1.64	5.47 ± 1.98	0.495
Direct Bilirubin, mg/dL	4.13 ± 1.18	4.06 ± 1.64	0.862
Amylase Serum, U/L	120.8 ± 172.29	127.19 ± 167.3	0.881

ALT Alanine aminotransferase; AST Aspartate aminotransferase
*Based on Independent T-test
^#Reference range for ALT, AST, total Bilirubin and direct bilirubin are 13–40 U/L, 11–37 U/L, 0.1–1.2 mg/dL and 0–0.3 mg/ dL respectively

ISSN: 1471-230X